Skip to main content
. 2021 Jun 1;5(8):bvab100. doi: 10.1210/jendso/bvab100

Table 2.

Timeline of endocrine toxicity by regimen

Immune checkpoint inhibitors regimen N (observed) N 25th percentile Median
(weeks)
75th percentile
Nivolumab 276 39 6.0 10.0 20
Atezolizumab 54 8 5.5 10.0 12
Pembrolizumab 117 21 3.0 8.0 20
Ipilimumab only 17 4 13.0 15.5 30
2+ agents, including ipilimumab 63 19 5.0 9.0 34
2+ agents, not including ipilimumab 24 4 11.0 23.5 44